Arrow CorAide Left Ventricular Assist System: Initial Experience of the Cardio-Thoracic Surgery Center in Pavia

Gazzoli, Fabrizio; Alloni, Alessia; Pagani, F.; Pellegrini, Carlo; Longobardi, Antonio; Ricci, Davide; Rinaldi, Mauro; Viganò, Mario

doi:10.1016/j.athoracsur.2006.05.026

Cited by 22 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CorAide centrifugal LVAD used sensorless flow estimates, high pump flow pulsatility response to changes in the status of the LV, and much lower LV suction levels during transient periods of low LV volume to successfully implement a physiologic automatic pump control algorithm in its European clinical trial. 19,21 In this limited trial of 21 patients, 72% of the total trial implant duration (16.6 patient-years) was run in automatic mode (personal unpublished data).…”

Section: Pump Flow Pulsatility and Automatic Physiologic Pump Controlmentioning

confidence: 99%

Axial and centrifugal continuous-flow rotary pumps: A translation from pump mechanics to clinical practice

Moazami¹,

Fukamachi

Kobayashi

et al. 2013

The Journal of Heart and Lung Transplantation

310

171

View full text Add to dashboard Cite

Section: Pump Flow Pulsatility and Automatic Physiologic Pump Controlmentioning

confidence: 99%

Axial and centrifugal continuous-flow rotary pumps: A translation from pump mechanics to clinical practice

Moazami¹,

Fukamachi

Kobayashi

et al. 2013

The Journal of Heart and Lung Transplantation

310

171

View full text Add to dashboard Cite

“…Most continuous-flow LVADs currently in clinical trials primarily use a fixed-speed control mode. The CorAide LVAD automatic control scheme, which was also developed at Cleveland Clinic, used automatic control of the pump output for the majority of the total implant duration in its European clinical trial and was the preferred operating mode for outpatients 13. The details about the aformentioned clinical trial will be published separately.…”

Section: Discussionmentioning

confidence: 99%

Introduction of fixed-flow mode in the DexAide right ventricular assist device

Saeed

Massiello

Shalli

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Background While some continuous-flow left ventricular assist device algorithms have been created to respond to varying patient physiology, very little research has been conducted on control of right ventricular support in univentricular and biventricular applications. The purpose of this study was to develop and evaluate a simple and reliable fixed-flow algorithm for the DexAide right ventricular assist device (RVAD). This algorithm automatically adjusts speed to maintain a target flow while preventing ventricular suction when a requested target flow exceeds available tricuspid flow. Methods Fixed-flow control mode was evaluated in 17 DexAide RVAD chronic bovine studies whose duration ranged from 14 - 90 days (33 ± 24 days). Targeted fixed-flow levels ranged from 4.0 to 6.5 L/min. Data were monitored on an hourly basis. Pump flow data were also recorded on a weekly basis to document the speed increment required to increase pump flow from 5 to 8 L/min at 0.5 L/min increments. Results The fixed-flow control mode was evaluated for a total duration of 5,283 hours without complications related to pump flow or left/right circulation imbalance. The pump speed varied between 2,000 – 3,220 rpm to maintain the flow constant at each target level. The average absolute mismatch between the target flow and measured flow was 0.6 ± 0.5 L/min. Conclusions Fixed-flow control mode with a predetermined maximum automatic pump speed can be safely and effectively used in the DexAide RVAD. It provided target flows by adjusting the pump speed while monitoring pump flow response to automatic speed increment requests.

show abstract

“…LVAD flow pulsatility is also incorporated as a suction detection mechanism. 18 Meanwhile, the RVAD uses fixed flow control with an added observer suction detection system which compares changes in flow with speed variation. 57 However, if low LVAD flow pulsatility is recorded, the dual pump controller responds by increasing the RVAD pump speed until either the LVAD flow pulsatility is restored, or the RVAD controller senses excessive RV unloading.…”

Section: Coraide/dexaidementioning

confidence: 99%

“…Pumping 5 L min 21 against 100 mmHg, the CorAide LVAD uses less than 6 W of power at 2850 RPM. 18 The DexAide RVAD was developed by modifying the CorAide device and has a diameter, length, weight, and device displacement volume of 44 mm, 48 mm, 280 g, and 69 mL, respectively. 51 The implantable centrifugal RVAD was developed by reducing the size of each primary vane, decreasing the number of primary vanes from seven to five and redesigning the volute.…”

Section: Coraide/dexaidementioning

confidence: 99%

Biventricular Assist Devices: A Technical Review

et al. 2011

View full text Add to dashboard Cite

The optimal treatment option for end stage heart failure is transplantation; however, the shortage of donor organs necessitates alternative treatment strategies such as mechanical circulatory assistance. Ventricular assist devices (VADs) are employed to support these cases while awaiting cardiac recovery or transplantation, or in some cases as destination therapy. While left ventricular assist device (LVAD) therapy alone is effective in many instances, up to 50% of LVAD recipients demonstrate clinically significant postoperative right ventricular failure and potentially need a biventricular assist device (BiVAD). In these cases, the BiVAD can effectively support both sides of the failing heart. This article presents a technical review of BiVADs, both clinically applied and under development. The BiVADs which have been used clinically are predominantly first generation, pulsatile, and paracorporeal systems that are bulky and prone to device failure, thrombus formation, and infection. While they have saved many lives, they generally necessitate a large external pneumatic driver which inhibits normal movement and quality of life for many patients. In an attempt to alleviate these issues, several smaller, implantable second and third generation devices that use either immersed mechanical blood bearings or hydrodynamic/magnetic levitation systems to support a rotating impeller are under development or in the early stages of clinical use. Although these rotary devices may offer a longer term, completely implantable option for patients with biventricular failure, their control strategies need to be refined to compete with the inherent volume balancing ability of the first generation devices. The BiVAD systems potentially offer an improved quality of life to patients with total heart failure, and thus a viable alternative to heart transplantation is anticipated with continued development.

show abstract

Arrow CorAide Left Ventricular Assist System: Initial Experience of the Cardio-Thoracic Surgery Center in Pavia

Cited by 22 publications

References 7 publications

Axial and centrifugal continuous-flow rotary pumps: A translation from pump mechanics to clinical practice

Axial and centrifugal continuous-flow rotary pumps: A translation from pump mechanics to clinical practice

Introduction of fixed-flow mode in the DexAide right ventricular assist device

Biventricular Assist Devices: A Technical Review

Contact Info

Product

Resources

About